InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami
November 4, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will participate in Wonderland: Miami, presented by Microdose. The event is set to take place Nov. 8-9, 2021, in Miami, Florida. Tryp’s chairman and CEO Greg McKee will participate in a […]
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
November 4, 2021
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/8YBVv […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia
November 2, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a phase 2a clinical trial. Conducted with Kevin […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Releases Entertainment Lineup for Premiere Psychedelic, Wellness Event
November 2, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced the list of entertainers that will be featured during its upcoming Meet Delic event. The event, scheduled for Nov. 6–7, 2021, in Las Vegas, is designed to be an immersive edutainment experience offering everything […]
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
November 2, 2021
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Breaking the Habit: Psychedelic Stigma Fades as […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Way Through Unique Psychedelic Drug Development Focus
November 1, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is nearing the launch of a phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as Prader-Willi Syndrome (“PWS”), hypothalamic obesity disorder resulting from the removal of a brain tumor, and binge eating dysfunction. […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Transforming Treatment of Fibromyalgia and Chronic Pain Conditions
October 29, 2021
In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a member Commenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as […]
InvestorNewsBreaks – Sprout AI Inc. (CSE: SPRT) to Provide Cultivation Services for Company Offering Plant-Based Medical Products
October 29, 2021
Sprout AI(CSE: SPRT), a technologically focused, sustainable vertical farming company that has developed scalable, AI-controlled aeroponic cultivation habitats, will be providing cultivation services for JT Medical. JT Medical has announced that it is accepting memorandums of understanding (“MOUs”) from researchers looking to obtain high-quality, repeatable batch, plant-based medical products derived from regulated plants. The company […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speakers for World’s Premiere Psychedelic, Wellness Event
October 27, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that COMPASS Pathways execs George Goldsmith and Ekaterina Malievskaia MD will be featured speakers at next month’s Meet Delic event. Meet Delic is a revolutionary, two-day immersive edutainment experience designed to gather together the world’s leading […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Successfully Synthesizes Novel Psilocin Analogue
October 27, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized a novel psilocin analogue, a tryptamine. This achievement means improved pharmaceutical properties to further strengthen MYCO’s library of patent-pending tryptamines. According to the announcement, the synthesis of the […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Is ‘One to Watch’
October 27, 2021
The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions Through an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Upcoming Pain Therapeutics Summit
October 26, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced that it will present at the 15th Annual Pain Therapeutics Summit. The event is slated to take place on Nov. 1-3, 2021, with Tryp’s presentation scheduled to begin at 11:15 a.m. Central Time […]
InvestorNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Lab Facility Enters Partnership with GT Research for Comarketing Efforts
October 26, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has inked a comarketing agreement focused on computational genetic analysis and trait optimization for cannabis and psychedelics. The agreement was signed through Delic Labs, which inked the deal with GTR Research Inc. (“GTR”). GTR is leading […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
October 21, 2021
Tryp announced its inclusion in the AdvisorShares Psychedelics ETF The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days Launched back in September […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study
October 21, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, reported that the U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on its upcoming Phase 2a study for eating disorders. According to the announcement, the FDA did not cite a reason for […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine
October 20, 2021
Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Founder of Synergy Soul to Headline at Meet Delic
October 19, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Brittany Hoogenboom will serve as a keynote speaker at Meet Delic on Nov. 7, 2021. Hoogenboom is the owner and founder of Synergy Soul, a brand focused on personal transformation through a holistic, integrated approach to life, business and […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Leveraging Wide-Ranging Business, Eyeing Opportunity in Multibillion Industry
October 18, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is servicing the growing interest within the psychedelic drug market, projected to grow at a 12.36% CAGR from $4.75 billion in 2020 to $10.75 billion by 2027, through the expansion of its wide-ranging business. “Simultaneously and in line with its goal of enabling billions […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803
October 15, 2021
Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation The partnership is the latest in a series of collaborations as the company prepares for Phase […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Included in AdvisorShares Psychedelics ETF
October 14, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced its inclusion in the AdvisorShares Psychedelics ETF (the “Fund”), currently trading under ticker symbol PSIL on the NYSE Arca exchange. According to the update, the Fund, launched in September 2021, is actively trading […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Collaboration to Provide Veterans with Free Ketamine Treatments
October 14, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced two new partnerships between Ketamine Wellness Centers LLC (“KWC”) and the Veterans Administration (“VA”) Community Care Networks of Illinois and Minnesota . According to the update, the nation’s largest chain of psychedelic wellness clinics, KWC, will offer ketamine treatments to […]
Delic Holdings (CSE: DELC) (OTCQB: DELCF) Reports Second Quarter Financial Results; Sets Up Business Pillars for Continued Growth
October 12, 2021
Delic Holdings Corp. (the “company” or “Delic”) reported Q2 revenues of $149,290 while realizing a strong gross profit margin of 87% The company has recently broadened its business verticals through the acquisition of Homestead, a psychedelic media distributor, and Ketamine Infusion Centers LLC, one of the largest chains of ketamine clinics in the U.S. Delic […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Duncan Trussell to Keynote at Meet Delic: The World’s Premiere Psychedelic and Wellness Event
October 12, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Duncan Trussell will serve as a keynote speaker at Meet Delic on Nov. 6, 2021. An actor and stand-up comedian, Trussell co-created and appears in the Netflix animated series “The Midnight Gospel” and regularly travels the country performing comedy […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference
October 12, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief […]
Microdose’s Miami Wonderland Event Takes Vision of Psychedelic Medicine’s Business Potential to the Stars
October 11, 2021
Date: Nov. 8-9, 2021 Venue: Adrienne Arsht Center for the Performing Arts, Miami Agenda: Two days of expert panels covering a variety of topics surrounding the psychedelics industry’s medicinal, corporate and regulatory impact and beyond Tickets and Registration Info: Visit https://microdose.buzz/wonderland/miami/ As the health and wellness industry evolves, a veritable flood of innovators searching for […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic
October 11, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin
October 11, 2021
Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://ibn.fm/NCORl). “Yale researchers found that […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Launch of New Website and Resources
October 8, 2021
Tryp Therapeutics recently launched a new website with updated resources to be featured on the site Over the next few weeks, the company will share key resources that will be the standout features of the new website Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Collaboration with University of Wisconsin Researchers to Evaluate TRP-8803
October 7, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, this morning announced a collaboration to support clinical pharmacology studies for Tryp’s proprietary drug product TRP-8803. Dr. Paul Hutson, Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy and Dr. […]
InvestorNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs Moves Forward with Strategic Steps toward Commercialization
October 6, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Delic Labs, which is part of the Delic Corp. family, has applied for a Health Canada 56 Research Exemption. Approval of the application allows Delic Labs scientists to perform research and tests on compounds in addition to psychedelic mushrooms, […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event
October 5, 2021
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world’s leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare
September 30, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced a first-of-its-kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Under the partnership, KIC will have access […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial
September 30, 2021
Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development
September 30, 2021
NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://ibn.fm/uFQY9 Innovative companies are looking outside […]
InvestorNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics
September 28, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on Nov. 7, 2021. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers that earned him 2009 and 2010 NBA championships. Odom […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining Psychiatry
September 28, 2021
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Investors Turning to Psychedelic Market as Renaissance Continues […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People
September 27, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits […]
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Looks Optimally Positioned to Benefit From Continued Growth Within the Psychedelic Wellness Sector
September 27, 2021
Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reiterates Engaging Lineup for Its Two-Day Immersive Edutainment Experience – Meet Delic
September 23, 2021
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today reiterated the full lineup of thought leaders, entrepreneurs, medical experts and entertainers taking part at its two-day premier Meet Delic psychedelics event. The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates
September 23, 2021
Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan Tryp executives have been meeting with investors at select conferences recently […]